Lineage Cell Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2017 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Lineage Cell Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2017 to Q3 2024.
  • Lineage Cell Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 53.4 %, a 13.7% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 53.4 -8.44 -13.7% Sep 30, 2024
Q2 2024 55.8 -8.5 -13.2% Jun 30, 2024
Q1 2024 56.6 -10.2 -15.3% Mar 31, 2024
Q4 2023 59.4 -8.71 -12.8% Dec 31, 2023
Q3 2023 61.8 -11.9 -16.1% Sep 30, 2023
Q2 2023 64.3 +9.64 +17.6% Jun 30, 2023
Q1 2023 66.7 +27.7 +70.8% Mar 31, 2023
Q4 2022 68.1 +42.2 +163% Dec 31, 2022
Q3 2022 73.7 +63.5 +621% Sep 30, 2022
Q2 2022 54.7 +43.4 +387% Jun 30, 2022
Q1 2022 39.1 +26.4 +207% Mar 31, 2022
Q4 2021 25.9 +12.1 +87.6% Dec 31, 2021
Q3 2021 10.2 -3.34 -24.6% Sep 30, 2021
Q2 2021 11.2 -2.58 -18.7% Jun 30, 2021
Q1 2021 12.7 -1.27 -9.08% Mar 31, 2021
Q4 2020 13.8 -0.33 -2.34% Dec 31, 2020
Q3 2020 13.6 -0.18 -1.31% Sep 30, 2020
Q2 2020 13.8 +3.35 +32% Jun 30, 2020
Q1 2020 14 +5.25 +60.1% Mar 31, 2020
Q4 2019 14.1 +7.36 +109% Dec 31, 2019
Q3 2019 13.8 +7.96 +138% Sep 30, 2019
Q2 2019 10.5 +3.82 +57.5% Jun 30, 2019
Q1 2019 8.74 +1.68 +23.8% Mar 31, 2019
Q4 2018 6.76 -0.5 -6.89% Dec 31, 2018
Q3 2018 5.79 -2.4 -29.3% Sep 30, 2018
Q2 2018 6.64 -2.36 -26.2% Jun 30, 2018
Q1 2018 7.06 -2.58 -26.8% Mar 31, 2018
Q4 2017 7.25 Dec 31, 2017
Q3 2017 8.18 Sep 30, 2017
Q2 2017 9 Jun 30, 2017
Q1 2017 9.64 Mar 31, 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.